In the coming days, weeks and months, as those eligible for this extra dose decide whether to roll up their sleeves, we can expect the public chatter to take all the varied tones we’ve heard over the past two years: indignation that our health authorities dare to suggest yet another vaccine dose, delight that another vaccine dose will boost waning immunity and everything in between.
Though it’s clear that the FDA is being tip-toe cautious, I love their decision. Let’s face it: Every time we have thought the coast was clear on Covid, we have been wrong. And every time we thought we were collectively immune enough from the virus — from prior disease or from the vaccines — we have been wrong. And, as with previous vaccine decisions, there is data, albeit early and not all peer-reviewed, that informed the FDA’s decision.
First and foremost, there is no evidence from any of the studies reported thus far — numbering hundreds of thousands of people who have received four vaccines — that the fourth vaccine is unsafe. Its side effects appear to resemble those of vaccine three: achy arms, a little fever, but nothing new.
Though disappointing, this was a mostly not-old group, all of whom were healthy enough to work full-time; it may be that such a group has little clinical protection to gain from improved antibody levels.
This study was not randomized or controlled; in all, 58% of people had received four vaccines and the remainder only three. Patients were followed for 40 days during the Omicron surge in Israel. Of note, uptake of the fourth vaccine was higher among those with higher socioeconomic status who might have easier access to early medical care and lower among the ultra-Orthodox Jewish population and among Arab citizens.
What then does all of this mean? Well, it’s complicated and open to interpretation according to one’s own already-established view. Surely, the two larger studies, which have not been peer-reviewed, show very compelling evidence of a real and important health benefit for older people, especially those in their 80s and 90s. For them, the fourth shot means a more confident return to a normal life.
The jury is still out, however, on the benefit, if any, for younger and healthier people. This is, in part, what made the FDA decide to set the “eligible” age at 50. Though the data looks good (though not peer-reviewed) for older Americans, inclusion of this not old, though not young group, is a bit of a leap.
The predicament of having to decide before studies are complete, however, is a common one. And when in this particular bind, the best step is the one the FDA appears to have taken: revert to the basics.
If the fourth dose is very effective in the very old, effective in the old and not-so-effective in the not-so-old, the human immune system probably is telling us something. Therefore, given the danger imposed by a rapidly moving infectious disease, waiting for the tidy data to demonstrate the open-and-shut evidence — or lack of evidence — for the fourth dose of Covid-19 vaccine may be in the rule book for academic publications but does a disservice to public health.
While we twiddle our thumbs, another variant may enter the population at a sprint like it happened in December with the Omicron variant. And once it hits, scrambling to get more shots into more arms is a losing strategy as we saw, also, in December.
